Navigation Links
Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that positive preclinical data will be presented at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled, "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities." The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.

In a porcine coronary model, data show continuous and controlled release of sirolimus, with the MiStent DES coating being eliminated from the stent within 45 to 60 days, and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott MULTI-LINK Vision™ Coronary Stent at 30 and 90 days in the challenging overlapping stents implant configuration.

James B. McClain, Ph.D., Senior Vice President of Micell, said, "Micell is uniting well-known DES stent components with a proprietary coating process to produce a fundamentally different DES. Our preclinical studies demonstrate a markedly consistent drug delivery profile with controlled, linear release of therapeutic levels of drug."

Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.

Elazer R. Edelman, M.D., Ph.D., commented, "The presented data, based on a thorough preclinical evaluation, validate the premise that Micell's unique coating process could produce a remarkable level of consistency and control in a drug-eluting stent." Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at the Massachusetts Institute of Technology and is a consultant to Micell.

Presentation Details

EuroPCR, Paris, France -- Wednesday, May 18, 15:00-16:30
Plenary session: Cardiovascular Innovation Pipeline – Coronary Heart Disease
MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities
Presented by James B. McClain, Ph.D., Senior Vice President, Micell Technologies

About the MiStent DES

The MiStent DES is a drug-eluting stent designed to optimize healing. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration. The MiStent DES is intended to deliver a precise therapeutic solution for coronary artery disease with the potential to avoid the long-term safety concerns associated with current drug-eluting stents.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days. In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES currently is being evaluated in international clinical studies.

The MiStent Drug Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

About Micell Technologies, Inc.

Micell Technologies™ is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell also is developing a drug-coated balloon for vascular interventions. Visit us at

Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc.

Contact: Micell Technologies
Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Micell Technologies Rapid Absorption Polymer DES System to be Presented at CRT 2009
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
4. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
5. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
6. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
7. Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine
8. Reportlinker Adds Biomarkers: Technologies and Global Markets
9. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
10. Life Technologies Names Dr. Ora Hirsch Pescovitz to its Board of Directors
11. China Green Material Technologies, Inc. Announces Change of Auditor to Marcum Bernstein & Pinchuk LLP
Post Your Comments:
(Date:10/8/2015)... 2015  Genetic testing for mutations beyond those currently ... more couples at risk of having a child with ... the 2015 American Society of Human Genetics (ASHG) Annual ... Baltimore, Maryland . The study is one of ... ) are presenting at the conference this week demonstrating ...
(Date:10/8/2015)... Oct. 8, 2015 Celemics, a global pioneer ... the North American market with the establishment of Celemics ... and Europe , has secured itself ... Enrichment methodology and sample preparation for DNA sequencing and ... hereditary and somatic genetic testing more accurately, quickly, and ...
(Date:10/8/2015)... 2015 Nobel Prize in Chemistry has been awarded to ... Aziz Sancar , who earned his PhD in molecular and cell ... one of three scientists who received the Nobel Prize for their ... a molecular level.  --> Aziz Sancar , who earned ... Dallas in 1977, is one of three scientists who ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
Breaking Biology Technology:
... was at a security conference and stayed at a hotel, ... claimed that they had implemented it so only those on ... ,I do not purchase wireless Internet service when Im at ... the seminar hosts office. Out of curiosity, on my second ...
... Commerce has announced that it is producing the Wisconsin ... Thursday, September 25, from 8:30 a.m. to 3:45 p.m. ... , ,Wisconsins medical device and technology cluster is ... state, said Department of Commerce (Commerce) Secretary Cory L. ...
... all things e-commerce will speak to cutting-edge Madisonians Thursday evening ... Club Majestic, 115 King Street in downtown Madison. , ,Nationally ... about how e-commerce is coming out of the weeds after ... Some companies are finally learning how to please consumers and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 Report ... thus far not quite delivered upon previous expectations of ... might be the breakthrough year in which wearables begin ... been expected. One of the main reasons is the ... disrupt not only the SmartWatches market, but the overall ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... new survey, Smart Marketing for Engineers TM : ... engineering professionals reveals insightful findings about engineers, preferences for ... of content engineers most value and trust, and where ... Marketers targeting technical audiences grapple with how to best ...
(Date:9/2/2015)... Biometric technology ... system which uses identical human characteristic such as ... and finger print. Increasing number of terror attacks ... which provides high level of security. Traditional security ... are vulnerable to attacks. Furthermore, Biometric technology uses ...
Breaking Biology News(10 mins):
... adults living closer to a fast food restaurant had a ... away from fast food, according to researchers at The University ... particularly strong among those with a lower income. ... of Public Health indicates higher BMI associates with residential ...
... relationship between the heritable risk for schizophrenia and low ... associated with cognitive impairments that may cause functional disability. ... to the risk for developing schizophrenia. For example, reduced ... Also, these deficits may be present in healthy relatives ...
... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ...
Cached Biology News:
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: